Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Financings

Phathom Pharmaceuticals, Inc.

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Update: about US$130M · US$16 a share · Guggenheim Securities +5
Dealers: Guggenheim Securities (co-lead), Cantor (co-lead), Raymond James, Needham & Company, H.C. Wainwright & Co., Craig-Hallum
Use of proceeds: General corporate purposes, including working capital and commercialization and research and development expenses
Jan 8, 2026

Read by 6ix AI from the company's releases